Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Humira's 'Unique' Number Of Patents Makes Biosimilar Entry Risky, Pfizer Says

Executive Summary

Pfizer wants to get its adalimumab biosimilar to market as soon as possible, but won’t say whether that’s before AbbVie's patents run out in 2023.

You may also be interested in...



Sharing Biosimilar Savings With Physicians Could Boost Market Share Over 50%, Trade Group Says

But even with the legislative and regulatory changes proposed by the Biosimilars Forum, market share would still not reach levels seen in Europe, an analysis by Avalere finds.

Two Months To Add Two Words – Biosimilar Supplement Review Times May Be Hindering Uptake

Biosimilar supplement approvals by the US FDA take on average about five months as sponsors request easier and quicker ways to update labels.

Pfizer Decides Not To Challenge AbbVie's Humira Biosimilar Patents

Pfizer is the seventh company to enter licensing agreement with AbbVie; it has completed development program for its adalimumab candidate.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS122875

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel